Atypical Parkinsonian Syndromes: A General Neurologists Perspective
Eur J Neurol 25:41-58, Deutschlander, A.B.,et al, 2018
Criteria for the Diagnosis of Corticobasal Degeneration
Neurol 80:496-503, Armstrong, M.J.,et al, 2013
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Cholinergic Vesicular Transporters in Progressive Supranuclesar Palsy
Neurol 58:1013-1018,997, Suzuki,M.,et al, 2002
Apolipoprotein E Genotype in Diverse Neurodegenerative Disorders
Ann Neurol 38:131-135, Schneider,J.A.,et al, 1995
Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993
Striatal D2 Receptor Status in Patients with Parkinson's Disease, Striatonigral Degeneration, and PSP, (PET)
Ann Neurol 31:184-192, Brooks,D.J.,et al, 1992
The Apomorphine Test in Parkinsonian Syndromes
JNNP 54:870-872, D'Costa,D.F.,et al, 1991
Sleep Abnormalities in Progressive Supranuclear Palsy
Ann Neurol 25:577-581, Aldrich,M.S.,et al, 1989
Progressive Supranuclear Palsy:Clinical Features & Response to Treatment in 16 Patients
Ann Neurol 13:273-278, Jackson,J.A.,et al, 1983
Progressive Supranuclear Palsy:Functional Analysis of the Response to Methysergide & Antiparkinsonian Agents
Neurol 31:1507-1518, Rafal,R.D.,et al, 1981
Progressive Supranuclear Palsy Clinico-Pathological Study of Four Cases
Brain 92:663, Behrman,S.,et al, 1969